Symbiotec Pharmalab Ltd
Symbiotec Pharmalab Q1 FY27: Revenue ₹218.2 Cr, EBITDA margin 21%
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Symbiotec Pharmalab Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Q1 FY27 EBITDA: Rs.
From Symbiotec Pharmalab Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9).
- API business revenue for Q1 FY27: ₹215.3 crores, up 6% YoY (Page 7).
- Q1 FY27 gross margins at 65%, up 300 basis points YoY (Page 9).
- API EBITDA increased 9% YoY to ₹65.8 crores, with ~30% EBITDA margin maintained (Page 7).
- Management commentary projects API revenue growth expected to further pick up in subsequent quarters (Page 6).
- New business segments (Complex Injectables and Biotech CDMO Services) currently incurring expenses with revenue expected to start in 6–12 months (Page 7, Page 8).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Symbiotec Pharmalab Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total gross capex invested as of June 30, 2026: ₹1,475 Cr; estimated total by end FY27: ₹1,666 Cr.
- API (Steroids & Hormones): ₹644 Cr invested; fully generating revenue; asset turns ~1.5X.
- Complex Injectables (Dual Chamber Vials - DCV): ₹356 Cr invested (₹376 Cr est.); majority capacity reserved with strategic partner.
- Biotech CDMO Services (400 KL + 14 KL): ₹471 Cr invested (₹584 Cr est.); backed by take-or-pay customer agreements.
- New API Capex: ₹4 Cr invested, estimated ₹63 Cr total; currently in discussions.
- New biologics facility (14 KL) at Ujjain under construction.
- Biotech plant expansion at SEZ Pithampur (280 KL) commissioned; biomanufacturing facility at Ujjain (400 KL) commissioned.
- 600 KL new CDMO capacities to be initiated, backed by customer agreement, revenue to commence in next 6–12 months.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Symbiotec Pharmalab Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Continue your research
What Symbiotec Pharmalab Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…
- SMS Pharmaceuticals Ltd (Q1 FY27)
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…
- Wanbury Ltd (Q1 FY27)
Q4FY26 Revenue from Operations: ₹164.58 Crore . Key concall takeaways from Wanbury Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Symbiotec Pharmalab Ltd Q1 FY27 results?
Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Q1 FY27 EBITDA: Rs.
What is Symbiotec Pharmalab Ltd share price analysis?
Symbiotec Pharmalab Ltd currently shows a neutral. The stock trades at a P/E of 61.0 with a market cap of ₹7,037 Cr. Investors should review the full earnings analysis for detailed insights.
Is Symbiotec Pharmalab Ltd planning capital expenditure?
Total gross capex invested as of June 30, 2026: ₹1,475 Cr; estimated total by end FY27: ₹1,666 Cr.
Keep Symbiotec Pharmalab Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.